Table 4 Changes in choroidal thickness during ranibizumab treatment according to neovascularization type

Type 2

Subfoveal CT (μm)

238.7 ± 75.8

223.4 ± 72.4

<0.001

224.0 ± 68.5

0.002

(n = 35)

 Mean

157.3 ± 45.1

153.3 ± 43.1

0.154

153.4 ± 42.6

0.163

 Superior

168.8 ± 47.9

165.6 ± 46.3

0.266

165.9 ± 45.3

0.313

 Nasal

155.9 ± 43.7

154.1 ± 43.5

0.511

153.2 ± 42.4

0.340

 Inferior

131.7 ± 39.8

129.2 ± 38.1

0.285

129.9 ± 38.3

0.456

 Temporal

172.5 ± 53.6

164.4 ± 49.4

0.011

164.5 ± 49.2

0.010

Type 3

Subfoveal CT (μm)

145.0 (102.8, 171.2)

124.0 (89.5, 175.8)

N/A

117.0 (83.4, 182.5)

N/A

(n = 4)

 Mean

112.6 (89.3, 150.8)

117.0 (80.0, 152.5)

N/A

117.0 (83.8, 182.5)

N/A

 Superior

125.0 (82.5, 193.8)

129.0 (72.8, 194.3)

N/A

131.0 (75.0, 195.3)

N/A

 Nasal

132.5 (98.5, 156.0)

129.5 (91.0, 167.3)

N/A

128.0 (87.5, 173.0)

N/A

 Inferior

88.5 (83.0, 93.3)

84.5 (77.8, 104.0)

N/A

84.5 (77.8, 110.0)

N/A

 Temporal

112.5 (84.0, 161.3)

116.5 (71.5, 160.0)

N/A

117.0 (71.3, 162.8)

N/A